Can a computer alert help doctors treat kidney disease better?
NCT ID NCT07430930
First seen Jun 26, 2026 · Last updated Aug 12, 2026 · Updated 3 times
Summary
This study tests whether a pop-up alert in electronic medical records helps doctors prescribe more recommended medications for chronic kidney disease (CKD). About 1,000 patients with CKD will be included, and their doctors will either see the alert or not. The goal is to see if the alert increases prescriptions of drugs like ACE inhibitors and SGLT2 inhibitors within 90 days.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Best practice alert and order set (clinical decision support tool)
- What this could lead to
- If successful, this could show that simple electronic alerts help doctors prescribe more guideline-recommended medications for CKD, potentially improving patient outcomes.
- What could go wrong
- This is a pragmatic trial focused on provider behavior, not a direct test of a new drug. It may not show clear benefits for patients, and results may not apply to other healthcare systems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 1,000 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Sep 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male or female, aged ≥18 years 2. Diagnosed with CKD defined by an eGFR ≤60 mL/min/1.732 on two occasions at least ≥3 months apart with most recent being ≤60 or eGFR 60-90 mL/min/1.73m2 with an uACR ≥30 mg/g or eGFR \>90 mL/min/1.73m2 with an uACR ≥30 mg/g. 3. Eligible to receive at least 1 of the following CKD GDMT: ACEi/ARB, SGLT2i, MRA or GLP-1 RA based on the following criteria. 4. To receive an ACEi/ARB: eGFR ≥15 ml/min/1.732 and have diagnosis of hypertension based on ICD10 code or proteinuria (uACR ≥30 mg/g). 5. To receive an SGLT2i: have heart failure (defined by ICD10 code); or T2D; or uACR ≥200 mg/g; or eGFR ≥20 ml/min/1.732. 6. To receive an MRA: ns-MRA: have an eGFR ≥25 ml/min/1.732, diagnosis of T2D, normal serum potassium (≤4.8 mmol/L) and albuminuria (\>30 mg/g). s-MRA: have an eGFR ≥45 ml/min/1.732 and heart failure, hyperaldosteronism, or refractory hypertension. 7. To receive a GLP-1 RA: have T2D. 8. Ability to take oral medication. Exclusion Criteria: 1. Allergy to the GDMT for which the patient is eligible 2. End-stage kidney disease 3. CKD stage 5 (eGFR \<15 ml/min/1.73m2) 4. Glomerulonephritis (by ICD-10 code) 5. Polycystic kidney disease (by ICD-10 code) 6. History of kidney transplant 7. End-stage heart failure 8. Eligible to receive ACEi/ARB but having blood pressure \<110/70 mmHg or have known renal artery stenosis 9. Eligible to receive SGLT2i but pregnant or breastfeeding, type 1 DM, history of euglycemic diabetic ketoacidosis or Fournier's gangrene based on ICD10 code. 10. Eligible to receive MRA but serum potassium ≥5 mmol/L, have office SBP \<100 mmHg, adrenal insufficiency based on ICD10 code or concomitant treatment with CYP3A4 inhibitors (Strong: grapefruit, grapefruit juice, itraconazole. Moderate: erythromycin. Weak: amiodarone). 11. Eligible to receive GLP-1 RA but pregnant; or found to have personal history of pancreatitis; or personal or family history of medullary thyroid cancer or MEN type 2 based on ICD10 code or gastroparesis based on ICD10 code. 12. Opted out of EHR-based research.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic kidney diseases are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Yale New Haven Health
New Haven, Connecticut, 06520, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a nurse and a neighbor help tame chronic disease?
- Which SGLT2 inhibitor wins? trial pits empagliflozin against dapagliflozin
- Does better dialysis keep parathyroid hormone in check?
- Biobank aims to unlock the mysteries of calciphylaxis
- Do kidney patients know why a fistula matters before dialysis?
- Potassium binder may let kidney patients keep Life-Saving heart drugs